To examine the promoter methylation status of DOK6 in AML patients and further analyze their clinical significance, the MSP and BSP primer sets and assays were designed at the CpG islands of the DOK6 gene promoter (Figure 1A). This evidence concerns the gene IBSP and acute myeloid leukemia.